UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2023.
Commission File Number: 001-40627

SOPHIA GENETICS SA
(Exact name of registrant as specified in its charter)

Rue du Centre 172
CH-1025 Saint-Sulpice
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOPHIA GENETICS SA

Date: May 12, 2023

By: /s/ Daan van Well

Name: Daan van Well

Title: Chief Legal Officer
<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Investor presentation Building a Data-Driven World dated May 12, 2023</td>
</tr>
</tbody>
</table>
Building a Data-Driven World

Dr. Jurgi CAMBLONG
Chief Executive Officer & Co-Founder

May 12, 2023
Cautionary Notices

This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

No offer to sell or buy
This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Other material information
This presentation does not contain all material information about SOPHIA GENETICS SA and its subsidiaries. No representations or warranties (expressed or implied) are made regarding the completeness of the information contained in this presentation. Refer to our Securities and Exchange Commission filings for additional information about us.

Market and industry data
This presentation contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Our estimates of addressable market (or similar concepts) are primarily based on epidemiological data, including incidence and prevalence estimates of addressable populations, as well as a range of price assumptions for our products taking into account differences in panel sizes, which may change over time. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. While we are not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty.

Research use only
SOPHIA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this presentation is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
We are a category defining software company on a mission to

Democratize Data-Driven Medicine
The Emergence of the Cloud and AI have transformed countless of industries

BUT, Healthcare is lagging
### Healthcare Data are Complex, Siloed and Diverse

**Diagnosis**

<table>
<thead>
<tr>
<th>GP Visit</th>
<th>Medical Oncologist</th>
<th>Radiologist</th>
<th>Biologist</th>
<th>Tumour Board</th>
<th>First line treatment</th>
<th>Monitoring</th>
<th>Progression</th>
<th>2nd line treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Clinical**

- Symptoms
- Coughing
- Shortness of breath
- Tiredness

- Patient and personal history
- Smoking history
- Performance status

- Treatment decision

- Quality of life

- PS
- PS
- PS
- PS
- PS
- Treatment decision

**Imaging**

- Chest X-ray
- Chest CT/PET scan
- Mammography

- CT scan
- PET/CT scan
- MRI scan

- CT scan
- CT scan
- CT scan

- CT scan

**Histopathology**

- PD-L1

**Genomics**

- NGS
- EGFR
- BRAF
- KRAS
- ROS1
- RET

- PD-L1

**Lab tests**

- Complete blood count

**Notes:**


© SOPHiA GENETICS 2023
Creating Network Effects in Healthcare is Difficult
given non-standardized methods and sensitive data
Collective Intelligence all-in-One Platform

to better and equally serve every patient around the world
Significantly Important for Key Diseases
driven by genomic alterations

Cancer
>25 Million New Cancer Cases per Year\(^1\)

Rare Diseases
~5% of the global population suffers from a Rare Disease\(^2\)

1. by 2040; 2. https://www.rarediseasesinternational.org/
Multimodal Data Brings Objectivity into human biology and diseases

Artificial intelligence / Machine learning

Visualization
Cohorting
Prediction

GENOMICS DATA
RADIOMICS DATA
CLINICAL DATA
BIOLOGICAL DATA
PROTEOMICS DATA
METABOLICOMICS DATA
DIGITAL PATHOLOGY DATA
Empowering Clinical and BioPharma Customers

Driving the data flywheel to benefit patients

**CLINICAL**  **BIOPHARMA**

**Discovery**
Apply benefits of proprietary AI/ML to late-stage discovery phases

**Deployment**
Expand access to genomic applications (both internal or 3rd party) by leveraging our global network

**Development**
Comprehensive suite of applications backed by AI-based algorithms to aid in harmonization and reporting
Transforming Healthcare through Strategic Collaborations

- Generate robust insights
- Break data silos
- Create a collective intelligence
- Accelerate adoption of precision medicine
Total Addressable Market is Significant

$35bn
Total addressable market

$21bn
Clinical
Diagnosis ($2bn)
Therapy Selection ($1bn)
Monitoring ($2.3bn)

$14bn
BioPharma
Insights and Awareness ($9bn)
Clinical TAM Supported by a Broad Set of Disease Indications

Disease Indications

- Somatic Oncology
- Liquid Biopsy
- HemOnc
- Hereditary Cancers
- Rare and Inherited Disorders

Clinical TAM

$21bn
Growing with our Customers Volume
via a consumption based SaaS model

Upload Data

SOPHiA Patented Algorithms

MUSKAT™
GINGER™
PEPPER™

Consumption based model

Interpret Data

Targeted Clinical Outcomes

University Hospitals
Comprehensive Cancer Centers
Specialty Labs
Central Labs

In-House Sequencing

Clinical Reporting

© SOPHiA GENETICS 2023
BioPharma TAM is an Emerging Opportunity

**BioPharma TAM**

$14bn

**Discovery**
Applying AI and ML to the proprietary data of our customers

**Development**
Powering predictive algorithms for better targeted drugs

**Deployment**
Entering markets worldwide with new solutions via our network
Key Financial Metrics

750+ Total customers (1)

430+ Core Genomics customers (1)

1.2 million+ Genomic Profiles Analyzed (2)

~77,000+ Genomic profiles analyzed in 1Q 2023 (2)

30% - 35% 2023 constant currency ex COVID revenue growth guidance (2)

37% 1Q2023 constant currency ex COVID revenue growth (2)

69% | 73% Q1 2023 IFRS gross profit margin | adjusted gross profit margin (3)

~$162M Cash, cash equivalents, & term deposits (2)

FN 1: Represents statistic as of 03/31/2023. FN 2: The Company is unable to provide a reconciliation of forward-looking constant currency revenue growth excluding COVID-19-related revenue to Revenue, the most comparable IFRS financial measure, due to the inherent difficulty in forecasting and quantifying the impact of foreign currency translation. FN 3: Please refer to appendix for IFRS to adjusted gross margin reconciliation.
Thank You
Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin for the Three Months Ended March 31, 2023

<table>
<thead>
<tr>
<th>Amounts in USD thousands (unaudited)</th>
<th>Three months ended March 31, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$13,966</td>
</tr>
<tr>
<td>Cost of revenue</td>
<td>(4,272)</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$9,694</td>
</tr>
<tr>
<td>Amortization of capitalized research and development expenses (1)</td>
<td>432</td>
</tr>
<tr>
<td>Adjusted gross profit</td>
<td>$10,126</td>
</tr>
</tbody>
</table>

Gross profit margin: 69%

Amortization of capitalized research and development expenses (1): 4%

Adjusted gross profit margin: 73%
Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth and Constant Currency Revenue Growth Excluding COVID-19-Related Revenue

(Amounts in USD thousands)

<table>
<thead>
<tr>
<th></th>
<th>2022 Q1</th>
<th>2023 Q1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reported Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y-o-Y Growth</td>
<td>$10,861</td>
<td>$13,966</td>
</tr>
<tr>
<td><strong>Current Period Constant Currency Impact</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constant Currency Revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y-o-Y Growth</td>
<td>$10,861</td>
<td>$14,584</td>
</tr>
<tr>
<td>COVID-19 Revenue</td>
<td>(331)</td>
<td>(125)</td>
</tr>
<tr>
<td>Constant Currency Impact on COVID-19 Revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Constant Current Revenue Excluding COVID-19 Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Y-o-Y Growth</td>
<td>$10,530</td>
<td>$14,464</td>
</tr>
</tbody>
</table>

© SOPHiA GENETICS 2023

Source: [https://www.sec.gov/Archives/edgar/data/1840706/000184070623000014/q12023sophiageneticssa6-k.htm](https://www.sec.gov/Archives/edgar/data/1840706/000184070623000014/q12023sophiageneticssa6-k.htm)
Notes to the Reconciliation of IFRS to Adjusted Financials

(1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.

(2) Damaged inventory write-off consists of expenses associated with the write-off of inventory that were damaged as a result of a refrigeration equipment malfunction. These expenses are not expected to be a recurring event in our business, but we expect such expenses could still be incurred from time to time.

(3) Amortization of intangible assets consists of costs related to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact, but we could continue to generate such expenses through future capital investments.

(4) Share-based compensation expense represents the cost of equity awards issued to our directors, officers, and employees. The fair value of awards is computed at the time the award is granted and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These expenses do not have a cash impact but remain a recurring expense for our business and represent an important part of our overall compensation strategy.

(5) Non-cash pension expense consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses calculated for IFRS purposes. The difference represents a non-cash expense, but pensions remain a recurring expense for our business as we continue to make contributions to our plans for the foreseeable future.

(6) Non-recurring IPO-related expenses represent expenses incurred for our initial public offering that were not capitalized and are not expected to be recurring during the ordinary course of our business.
Consistent Growth in Analysis Volume
accelerated momentum of analysis volume conducted on our platform going into 2023

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Analyses</td>
<td>17k</td>
<td>19k</td>
<td>21k</td>
<td>23k</td>
<td>25k</td>
<td>27k</td>
<td>29k</td>
<td>31k</td>
<td>33k</td>
<td>35k</td>
<td>37k</td>
<td>39k</td>
<td>41k</td>
<td>43k</td>
<td>45k</td>
<td>47k</td>
<td>49k</td>
<td>51k</td>
<td>53k</td>
<td>55k</td>
<td>57k</td>
<td>59k</td>
<td>61k</td>
<td>63k</td>
<td>65k</td>
</tr>
<tr>
<td>Core Genomics Analyses (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 Analyses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: SOPHiA Q1 2021 E4, https://www.sophia-genetics.com/sections/analysis/volumes/1866774/30118667743330091668125636martin663d9f64.html
Note: Includes analysis volume from all Core Genomics Customers using dry lab, bundle access, and integrated access models.